Drugs · acquisition-cost intelligence
testosterone
· ingredient testosterone3-oxoandrosten (4) derivatives· TESTOSTERONE 20.25 mg/1.25g; TESTOSTERONE 40.5 mg/2.5g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$2.97
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other testosterone products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| testosterone | $0.45945 | −$2.51 |
| testosterone | $0.61771 | −$2.35 |
| AndroGel | $0.65670 | −$2.31 |
| Testosterone | $0.91844 | −$2.05 |
| Testim | $2.24 | −$0.73250 |
| Depo-Testosterone | $5.41 | +$2.44 |
| AZMIRO | $11.19 | +$8.23 |
| testosterone cypionate | $11.19 | +$8.23 |
Medicare Part D coverage · CY2026
On 133 plan formularies · typical tier 4
Prior auth 85% · Step therapy 0% · Quantity limit 71% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.